JAGX
NASDAQ
US
Jaguar Health, Inc. - Common Stock
$0.40
▼ $-0.01
(-1.48%)
Vol 198K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.5M
ROE
-582.9%
Margin
-341.9%
D/E
546.58
Beta
0.08
52W
$1–$33
Wall Street Consensus
7 analysts · Apr 20263
Strong Buy
3
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%
Next Report
May 13, 2026
EPS Estimate: $-2.08
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-2.08 | — | — |
| Sep 2025 | $-5.18 | $-6.28 | $-1.10 |
| Jun 2025 | $-7.27 | $-10.26 | $-2.99 |
| Mar 2025 | $-18.36 | $-16.70 | +$1.66 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $3.1M | $3.5M | $2.2M | $3.0M | $3.1M |
| Net Income | -$9.9M | -$9.9M | -$10.5M | -$10.4M | -$9.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -426.5% | -320.9% | -426.5% | -426.5% | -426.5% | -582.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -349.4% | -343.9% | -344.2% | -344.2% | -344.2% | -341.9% |
| Gross Margin | 82.3% | 82.3% | 81.9% | 81.9% | 81.9% | 81.9% |
| D/E Ratio | 366.98 | 868.63 | 366.98 | 366.98 | 366.98 | 546.58 |
| Current Ratio | 0.95 | 1.08 | 0.95 | 0.95 | 0.95 | 0.81 |
Key Ratios
ROA (TTM)
-79.5%
P/S (TTM)
0.30
P/B
1.2
EPS (TTM)
$-54.06
CF/Share
$-3.41
Rev Growth 3Y
+39.2%
52W High
$33.25
52W Low
$1.00
$1.00
52-Week Range
$33.25
Financial Health
Free Cash Flow
-$4.7M
Net Debt
$28.4M
Cash
$3.5M
Total Debt
$31.9M
As of Sep 30, 2025
How does JAGX compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
JAGX valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
0.3
▼
94%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
1.2
▼
42%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
JAGX profitability vs Pharmaceuticals peers
ROE
-582.9%
▼
974%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-341.9%
▼
622%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
81.9%
▲
20%
above
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-79.5%
▼
112%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
JAGX financial health vs Pharmaceuticals peers
D/E ratio
546.6
▲
35392%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
0.8
▼
76%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
0.1
▼
92%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
JAGX fundamentals radar
JAGX
Peer median
Industry
JAGX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
JAGX vs peers: key metrics
Latest News
No related news yet